Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Roche Stories

2009-11-10 12:00:00

MENLO PARK, Calif., Nov. 10 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, announced today that its Center for Neuroscience has entered into a research collaboration with F. Hoffmann-La Roche to study procedures and treatments for cognition impairments in neurological and psychiatric conditions such as Alzheimer's disease, depression and schizophrenia. Research will take place in SRI's laboratories in Menlo Park, California. "SRI's...

2009-11-05 15:00:00

BRISBANE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2009. InterMune reported a net loss for the third quarter of 2009 of $8.8 million, or $0.19 per share, compared with a net loss of $14.0 million, or $0.36 per share, in the third quarter of 2008. Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "The third quarter and recent weeks...

2009-11-03 07:15:00

BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- Pharmasset, Inc (Nasdaq: VRUS) and InterMune, Inc. (Nasdaq: ITMN) today announced results from all patient cohorts of the INFORM-1 trial, an innovative Phase 1 study of two direct-acting antiviral (DAA) compounds administered without interferon or ribavirin for the treatment of patients chronically infected with the hepatitis C virus (HCV).(i) The study, conducted by Roche as part of its collaborations with InterMune and Pharmasset, combined the...

2009-09-29 06:00:00

BRISBANE, Calif., Sept. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that its partner Roche has begun dosing in a Phase 1b multiple ascending dose (MAD) study of ITMN-191 (RG7227) boosted by low-dose ritonavir in patients chronically infected with hepatitis C virus (HCV) genotype-1. Ritonavir boosting is an option to enhance and improve pharmacokinetic profiles of protease inhibitors. It is well established in the treatment of HIV where it leads to more...

2009-09-15 15:53:00

THOUSAND OAKS, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Court's decision that Roche's peg-EPO product, Mircera, infringes four Amgen patents ('868, '698, '933 and '422) relating to recombinant erythropoietin (EPO) and processes for making it. Regarding a fifth patent ('349), the Federal Circuit reversed the holding of non-infringement by the District Court and...

2009-09-13 13:15:00

SAN FRANCISCO, Sept. 13 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that two new observational studies concluded that influenza patients treated with Tamiflu(R) (oseltamivir phosphate) had significantly higher survival rates than untreated patients. The studies, examining nearly 1,000 people, analyzed outcomes for two different groups -adults and children diagnosed with the highly pathogenic A (H5N1) avian influenza and adults hospitalized with seasonal influenza....

2009-09-10 07:46:00

NEW YORK, Sept. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. World Cancer Therapies Market http://www.reportlinker.com/p0109886/World-Cancer-Therapies-Market.html This report analyzes the global market for Cancer Therapies in US$ Billion. The specific product segments analyzed are Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immunotherapy. Annual forecasts for the global market is provided for the period of 2006...

2009-09-08 09:11:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Prescription Drugs http://www.reportlinker.com/p0131233/Prescription-Drugs.html This report analyzes the worldwide markets for Prescription Drugs in US$ Billion by the following therapeutic class - Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists,...

2009-09-08 09:07:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Small Molecule Kinase Inhibitors http://www.reportlinker.com/p0131227/Small-Molecule-Kinase-Inhibitors.html This report analyzes the Global Market for Small Molecule Kinase Inhibitors in Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb, and Others. Annual forecasts are provided for the...

2009-09-08 08:59:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. FoodService Disposables http://www.reportlinker.com/p0131234/FoodService-Disposables.html This report analyzes the US market for FoodService Disposables in Millions of US$ by the following Product Types: Cups and Lids, Containers, Dinnerware, Napkins, and Others. This report also analyzes the US Market for Foodservice Disposables by End-Use Segments: Restaurants,...